Stocks Health care DNTH
NASDAQ · Health careDianthus Therapeutics, Inc. (DNTH)
It posted a net loss of $202.1M. In fiscal 2025 capital spending exceeded operating cash flow by $129.3M. At September 30, 2026 it held $55.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about Dianthus Therapeutics, Inc.
- Net worth
- Dianthus Therapeutics, Inc. has a market value (market cap) of $5B at the latest share price, and shareholders' equity of $1.2B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $2M (-67.3% year on year), with a net loss of $162.3M.
- Cash flow
- In fiscal 2025 operations used $129.1M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Dianthus Therapeutics, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Dianthus Therapeutics, Inc. does
Dianthus Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker DNTH.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $2M | -$162.3M | -$4.20 | -$129.3M |
| 2024 | $6.2M | -$85M | -$2.55 | -$78.3M |
| 2023 | $2.8M | -$43.6M | -$8.45 | -$37M |
| 2022 | n/a | -$28.5M | -$32.57 | -$29.4M |
| 2021 | n/a | -$71.1M | -$32.57 | -$60.8M |
| 2020 | n/a | -$74.9M | -$43.17 | -$64.4M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where DNTH ranks in Health care
Latest SEC filings
What Dianthus Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 4, 2026
- November 4, 2026
- October 30, 2026Passive stake (5% or more) SCHEDULE 13G
- September 18, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026Passive stake (5% or more) SCHEDULE 13G
- August 7, 2026Passive stake changed SCHEDULE 13G/A
- August 7, 2026Passive stake (5% or more) SCHEDULE 13G
- August 4, 2026
- August 4, 2026
Insider trades
What the people running Dianthus Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $4.8M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 17, 2026 | Carr EdwardCHIEF ACCOUNTING OFFICER | Exercised options | 20,000 | $357.6K |
| September 17, 2026 | Carr EdwardCHIEF ACCOUNTING OFFICER | Soldpre-planned (10b5-1) | 7,928 | $796.2K |
| September 17, 2026 | Carr EdwardCHIEF ACCOUNTING OFFICER | Soldpre-planned (10b5-1) | 6,771 | $686.4K |
| September 17, 2026 | Carr EdwardCHIEF ACCOUNTING OFFICER | Soldpre-planned (10b5-1) | 3,501 | $358.5K |
| September 17, 2026 | Carr EdwardCHIEF ACCOUNTING OFFICER | Soldpre-planned (10b5-1) | 1,100 | $113.5K |
| September 17, 2026 | Carr EdwardCHIEF ACCOUNTING OFFICER | Soldpre-planned (10b5-1) | 700 | $73.1K |
| September 1, 2026 | Randhawa SimratEVP, Head of R&D | Exercised options | 7,500 | $134.1K |
| September 1, 2026 | Randhawa SimratEVP, Head of R&D | Exercised options | 6,249 | $136K |
Who owns DNTH
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Fmr LLC13G, passive with 1 related filers | 15% | November 5, 2025 |
| T. Rowe Price Investment Management, Inc.13G, passive | 12.1% | August 7, 2026 |
| Fairmount Healthcare Fund II LP13D, may seek influence with 5 related filers | 9.99% | April 1, 2024 |
| Wellington Management Group LLP13G, passive with 3 related filers | 5.9% | August 13, 2026 |
| Vanguard Capital Management13G, passive | 5.08% | October 30, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 269 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Fmr LLC | 8,199,893 | +432,207 |
| BlackRock, Inc. | 4,123,822 | +948,119 |
| Wellington Management Group Llp | 3,229,882 | +634,099 |
| Fairmount Funds Management LLC | 2,537,191 | 0 |
| State Street Corp | 2,357,440 | +958,527 |
| Vanguard Capital Management LLC | 2,159,568 | +128,319 |
| Avidity Partners Management LP | 2,104,184 | -2,104,184 |
| Octagon Capital Advisors LP | 1,841,667 | -105,000 |
| TCG Crossover Management, LLC | 1,676,624 | 0 |
| Fred Alger Management, LLC | 1,302,493 | +140,570 |
| Geode Capital Management, LLC | 1,258,502 | +342,291 |
| Venrock Adviser, LLC | 1,180,000 | 0 |
| UBS Group AG | 1,140,260 | +358,978 |
| Deerfield Management Company, L.P. | 1,125,313 | +105,500 |
| Jennison Associates LLC | 1,021,763 | +536,627 |
| Polar Capital Holdings Plc | 1,018,726 | -57,283 |
| Citadel Advisors LLC | 974,911 | -635,572 |
| Franklin Resources Inc | 968,983 | +801 |
| Baker Bros. Advisors LP | 852,164 | 0 |
| Logos Global Management LP | 800,000 | +400,000 |
Insiders
3 insiders reported holding 84,292 shares in total, about $7.5M at the last price.
| Holder | Shares |
|---|---|
| Garcia MarinoCEO AND PRESIDENT, Director | 65,292 |
| Veness Adam MSVP, General Counsel and Sec. | 15,000 |
| Randhawa SimratEVP, Head of R&D | 4,000 |
Questions about DNTH
What does Dianthus Therapeutics, Inc. do?
Dianthus Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as DNTH. Its shares trade on NASDAQ under the ticker DNTH.
What is Dianthus Therapeutics, Inc.'s net worth?
Dianthus Therapeutics, Inc. has a market value (market cap) of $5B at the latest share price, and shareholders' equity of $1.2B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Dianthus Therapeutics, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $202.1M.
When did Dianthus Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the planned insider sale from November 9, 2026.
When is Dianthus Therapeutics, Inc.'s next earnings report?
Dianthus Therapeutics, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare DNTH with
Follow DNTH
Get an email when Dianthus Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Dianthus Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.